0001437749-16-028526.txt : 20160328 0001437749-16-028526.hdr.sgml : 20160328 20160328210431 ACCESSION NUMBER: 0001437749-16-028526 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160324 FILED AS OF DATE: 20160328 DATE AS OF CHANGE: 20160328 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RESPONSE BIOMEDICAL CORP CENTRAL INDEX KEY: 0000806888 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1781 - 75TH AVENUE W. CITY: VANCOUVER STATE: A1 ZIP: V6P6P2 BUSINESS PHONE: 604-456-6010 MAIL ADDRESS: STREET 1: 1781 - 75TH AVENUE W. CITY: VANCOUVER STATE: A1 ZIP: V6P6P2 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shuster Lewis CENTRAL INDEX KEY: 0001471131 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50571 FILM NUMBER: 161533433 MAIL ADDRESS: STREET 1: 421 BRIDOON TERRACE CITY: ENCINITAS STATE: CA ZIP: 92024 4 1 rdgdoc.xml FORM 4 X0306 4 2016-03-24 0000806888 RESPONSE BIOMEDICAL CORP RBM 0001471131 Shuster Lewis 1781 - 75TH AVENUE W. VANCOUVER A1 V6P 6P2 BRITISH COLUMBIA, CANADA 1 Deferred Share Unit Award (Right to Receive) 0 2016-03-24 4 A 0 36764 0 A Common Stock 36764 36764 D Stock Option (right to buy) 0.85 2016-03-24 4 A 0 5000 0 A 2026-03-23 Common Stock 5000 5000 D Reporting person has received an exempt award of Deferred Share Units ("DSUs") under the Issuer's Non-Employee Directors Deferred Share Unit Plan (the "Plan"). DSUs represent a right to receive shares of the issuer's common stock (or, in the sole discretion of the Issuer's Board of Directors following a Change in Control as defined in the Plan, cash, securities or a combination of cash and securities equal to the fair market value thereof) upon the reporting person's termination of service for the issuer. The DSUs are immediately vested and expire 90-days following the reporting person's Termination Date as defined in the Plan. Exercise prices shown are denominated in Canadian dollars. Subject to the reporting person's continued service as a director of the company through each vesting date, 100% of the shares subject to the option shall vest and become exercisable on March 24, 2017. /s/ Anastasios Tsonis, Attorney-in-Fact 2016-03-28